标题
Inhibiting RRM2 to enhance the anticancer activity of chemotherapy
作者
关键词
Ribonucleotide reductase subunit M2, Chemotherapy, Chemoresistance, Small interfering RNA, RRM2 inhibitors, Kinase inhibitors
出版物
BIOMEDICINE & PHARMACOTHERAPY
Volume 133, Issue -, Pages 110996
出版商
Elsevier BV
发表日期
2020-11-21
DOI
10.1016/j.biopha.2020.110996
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Proteomic Level Changes on Treatment in MCF-7/DDP Breast Cancer Drug-Resistant Cells
- (2020) Gongshen Jin et al. Anti-Cancer Agents in Medicinal Chemistry
- MicroRNA-4500 Inhibits Migration, Invasion and Angiogenesis of Breast Cancer Cells via RRM2-dependent MAPK Signaling Pathway
- (2020) Shaoying Li et al. Molecular Therapy-Nucleic Acids
- Downregulation of miR-125b-5p and Its Prospective Molecular Mechanism in Lung Squamous Cell Carcinoma
- (2020) Shu-Ping Huang et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- ERK Inhibitor Enhances Everolimus Efficacy through Attenuation of dNTP Pools in Renal Cell Carcinoma
- (2019) Yun Zou et al. Molecular Therapy-Nucleic Acids
- The current state and future directions of RNAi-based therapeutics
- (2019) Ryan L. Setten et al. NATURE REVIEWS DRUG DISCOVERY
- MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine based chemotherapy
- (2019) Huimin Lu et al. BIOSCIENCE REPORTS
- Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis
- (2019) Wenxiu Qi et al. BIOCHEMICAL PHARMACOLOGY
- Long noncoding RNA LINC00958 regulates cell sensitivity to radiotherapy through RRM2 by binding to microRNA‐5095 in cervical cancer
- (2019) Hui Zhao et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Identification of lncRNA NEAT1/miR‐21/RRM2 axis as a novel biomarker in breast cancer
- (2019) Dongling Quan et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells
- (2019) Myoungjae Kim et al. MOLECULES
- The Non-Canonical Aspects of MicroRNAs: Many Roads to Gene Regulation
- (2019) Christiaan J. Stavast et al. Cells
- LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2
- (2019) Na Huang et al. Frontiers in Oncology
- miR-140-3p impedes the proliferation of human cervical cancer cells by targeting RRM2 to induce cell-cycle arrest and early apoptosis
- (2019) Jiajia Ma et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment
- (2018) Xiao Zhao et al. BIOMATERIALS
- A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors
- (2018) Laeeq Malik et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction
- (2018) Ping Chen et al. CLINICAL SCIENCE
- Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo
- (2018) Shuhei Shinoda et al. Oncotarget
- Nano-Diamino-Tetrac (NDAT) Enhances Resveratrol-Induced Antiproliferation by Action on the RRM2 Pathway in Colorectal Cancers
- (2018) André Wendindondé Nana et al. Hormones & Cancer
- siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin
- (2018) Shuquan Zheng et al. Molecular Therapy-Nucleic Acids
- DHS (trans−4,4′-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2)
- (2018) Chi-Wei Chen et al. ONCOGENE
- Liposomal curcumin alters chemosensitivity of breast cancer cells to Adriamycin via regulating microRNA expression
- (2017) Siying Zhou et al. GENE
- Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
- (2017) Mukundan Baskar Mannargudi et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2)
- (2017) Guanggai Xia et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2
- (2017) Min Tu et al. Molecular Cancer
- Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype
- (2017) Jian Teng et al. NEURO-ONCOLOGY
- Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates
- (2017) Gonzalo Lopez et al. PLoS One
- Suppression of pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer to gemcitabine and 5FU, and inhibits the formation of pancreatic cancer stem like cells
- (2017) Jae Hee Cho et al. Oncotarget
- Targeting RRM2 and Mutant BRAF Is a Novel Combinatorial Strategy for Melanoma
- (2016) N. Fatkhutdinov et al. MOLECULAR CANCER RESEARCH
- Precision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal Medicine
- (2016) Zhijun Wang et al. MOLECULES
- Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640
- (2016) Clayton S. Lewis et al. Oncotarget
- Network-based approach to identify prognostic biomarkers for estrogen receptor–positive breast cancer treatment with tamoxifen
- (2015) Rong Liu et al. CANCER BIOLOGY & THERAPY
- Gemcitabine resistance in pancreatic ductal adenocarcinoma
- (2015) Yoav Binenbaum et al. DRUG RESISTANCE UPDATES
- Targeting Ribonucleotide Reductase M2 and NF- B Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
- (2015) K. N. Shah et al. MOLECULAR CANCER THERAPEUTICS
- Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer
- (2014) Rouzbeh Daylami et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- miR-211 Modulates Gemcitabine Activity Through Downregulation of Ribonucleotide Reductase and Inhibits the Invasive Behavior of Pancreatic Cancer Cells
- (2014) Mina Maftouh et al. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
- Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies
- (2014) Y Aye et al. ONCOGENE
- Establishment of human pancreatic cancer gemcitabine-resistant cell line with ribonucleotide reductase overexpression
- (2014) CONGFEI WANG et al. ONCOLOGY REPORTS
- Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival and Tamoxifen Resistance
- (2014) Nagireddy Putluri et al. NEOPLASIA
- Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA
- (2013) Jie Gao et al. BIOMATERIALS
- A Small-Molecule Blocking Ribonucleotide Reductase Holoenzyme Formation Inhibits Cancer Cell Growth and Overcomes Drug Resistance
- (2013) B. Zhou et al. CANCER RESEARCH
- Targeting ribonucleotide reductase for cancer therapy
- (2013) Jimin Shao et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers
- (2013) Charles A. Kunos et al. GYNECOLOGIC ONCOLOGY
- Small Interfering RNA (siRNA)-Mediated Silencing of the M2 Subunit of Ribonucleotide Reductase
- (2013) Meng Zhang et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia
- (2013) Rebecca B. Klisovic et al. LEUKEMIA & LYMPHOMA
- AKT-Induced Tamoxifen Resistance Is Overturned by RRM2 Inhibition
- (2013) Khyati N. Shah et al. MOLECULAR CANCER RESEARCH
- Differential Processing of let-7a Precursors Influences RRM2 Expression and Chemosensitivity in Pancreatic Cancer: Role of LIN-28 and SET Oncoprotein
- (2013) Yangzom Doma Bhutia et al. PLoS One
- Identifying miRNAs, targets and functions
- (2012) B. Liu et al. BRIEFINGS IN BIOINFORMATICS
- Cyclin F-Mediated Degradation of Ribonucleotide Reductase M2 Controls Genome Integrity and DNA Repair
- (2012) Vincenzo D'Angiolella et al. CELL
- A Dose Escalation and Pharmacodynamic Study of Triapine and Radiation in Patients With Locally Advanced Pancreas Cancer
- (2012) Ludmila Katherine Martin et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors
- (2012) Amir Mortazavi et al. INVESTIGATIONAL NEW DRUGS
- Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study
- (2012) Charles Kunos et al. Journal of Translational Medicine
- Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells
- (2012) G. Pontarin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma
- (2011) R. J. Jones et al. BLOOD
- A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
- (2010) Srikala S. Sridhar et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical Cancer
- (2010) C. A. Kunos et al. CLINICAL CANCER RESEARCH
- siRNA Knockdown of Ribonucleotide Reductase Inhibits Melanoma Cell Line Proliferation Alone or Synergistically with Temozolomide
- (2010) Jonathan E. Zuckerman et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium
- (2010) Natasha B. Leighl et al. Journal of Thoracic Oncology
- Ribonucleotide Reductase Inhibition Enhances Chemoradiosensitivity of Human Cervical Cancers
- (2010) Charles A. Kunos et al. RADIATION RESEARCH
- Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase
- (2009) Lijun Zhu et al. BIOCHEMICAL PHARMACOLOGY
- Implication of Checkpoint Kinase-dependent Up-regulation of Ribonucleotide Reductase R2 in DNA Damage Response
- (2009) Yong-Wei Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Modulating Radiation Resistance by Inhibiting Ribonucleotide Reductase in Cancers with Virally or Mutationally Silenced p53 Protein
- (2009) Charles A. Kunos et al. RADIATION RESEARCH
- Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine
- (2008) J Souglakos et al. BRITISH JOURNAL OF CANCER
- Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors
- (2008) Romano Danesi et al. PHARMACOGENOMICS
- Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients
- (2008) Ioannis Boukovinas et al. PLoS One
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started